Namodenoson

DRUG3 trials

Sponsors

Can-Fite Biopharma Ltd., Can-Fite BioPharma

Conditions

CirrhosisHepatocellular CarcinomaNASH - Nonalcoholic SteatohepatitisNon-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

Phase 2

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

RecruitingNCT04697810

Can-Fite BioPharmaNASH - Nonalcoholic Steatohepatitis

Start: 2021-12-10End: 2025-10-15Target: 114Updated: 2024-07-31

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

RecruitingCTIS2023-510548-19-00

Can-Fite Biopharma Ltd.Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

Start: 2023-03-02Target: 70Updated: 2025-06-02

Phase 3

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

RecruitingNCT05201404

Can-Fite BioPharmaCirrhosis, Hepatocellular Carcinoma

Start: 2023-03-15End: 2026-10-31Target: 471Updated: 2025-04-29